Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | MELK | Q14680 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26516664 | 0.86 | JAK2 (0.41) | JAK2JAK3PTK2KDR | |
| SCHEMBL30360602 | 0.86 | JAK2 (0.41) | JAK2JAK3PTK2KDR | |
| SCHEMBL26516659 | 0.84 | PIK3CA (0.41) | PARP1PARP2JAK2JAK3PTK2 | |
| SCHEMBL30360613 | 0.84 | PIK3CA (0.41) | PARP1PARP2JAK2JAK3PTK2 | |
| SCHEMBL26119662 | 0.83 | OPRM1 (0.41) | JAK2JAK3PTK2KDR | |
| SCHEMBL24266163 | 0.83 | KCNH2 (0.44) | GPR119KCNH2PARP1PARP2ADORA2B | |
| SCHEMBL26516654 | 0.82 | CCR2 (0.41) | JAK2JAK3PTK2KDR | |
| SCHEMBL26119124 | 0.81 | CCR2 (0.47) | JAK2JAK3PTK2 | |
| SCHEMBL24266726 | 0.78 | KCNH2 (0.43) | GPR119KCNH2PARP1PARP2ADORA2B | |
| SCHEMBL29399633 | 0.78 | KCNH2 (0.43) | GPR119KCNH2PARP1PARP2ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115956077-A | Substituted heteroaryl compounds as TLR9 inhibitors | 百时美施贵宝公司 | 2023-04-11 | — | — | CN | claimed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | GPR119 163/4885KCNH2 3744/4885PARP1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.